Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical China

China Drug Registration Proposal Requires Clinical Trials For Follow-On Biologics – Sidley Austin

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

U.S.-based law firm also advises China to incorporate international standards for pharmacovigilance and adopt GMPs for APIs, in comments submitted to China’s SFDA.

You may also be interested in...



Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter

3SBio, the first Chinese biotechnology company to list on NASDAQ, reported strong second-quarter earnings for its lead EPO and thrombopoietin products and is on track to launch a pre-filled syringe EPO product in China by year-end, the firm announced Aug. 8

Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter

Firm’s EPO product gains exclusive contract for 19 Chinese military hospitals in Q2.

Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter

Firm’s EPO product gains exclusive contract for 19 Chinese military hospitals in Q2.

Table

View full table

Topics

Tags:
BioPharmaceutical China
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS066051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By